The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Insulet's revenues will grow 24.8% and EPS will remain in the red.
The average estimate for revenue is $58.9 million. On the bottom line, the average EPS estimate is -$0.21.
Last quarter, Insulet reported revenue of $54.8 million. GAAP reported sales were 23% higher than the prior-year quarter's $44.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at -$0.26. GAAP EPS were -$0.26 for Q3 against -$0.29 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 44.5%, 290 basis points better than the prior-year quarter. Operating margin was -15.5%, 640 basis points better than the prior-year quarter. Net margin was -22.7%, 770 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $212.7 million. The average EPS estimate is -$1.07.
The stock has a one-star rating (out of five) at Motley Fool CAPS, with 72 members out of 113 rating the stock outperform, and 41 members rating it underperform. Among 41 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 27 give Insulet a green thumbs-up, and 14 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Insulet is outperform, with an average price target of $22.91.
Is Insulet the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Insulet to My Watchlist.